EUCTR2016-002066-32-BE进行中（未招募）1 期
Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study with 24-month Open-label Follow up of Oleogel S10 in Patients with Inherited Epidermolysis Bullosa - EASE study
Amryt Research Limited0 个研究点目标入组 192 人开始时间: 2018年1月17日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 192
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •A patient will be eligible for study participation only if all of the following criteria apply:
- •1. Male and female patients aged =4 years with the following subtypes of inherited EB: JEB, DEB, and Kindler syndrome [Note: Children =21 days old and <4 years may be included only after confirmation by the Independent Data Monitoring Committee (IDMC) upon review of the safety and bioanalytical data at the interim safety review stage]
- •2. Patients with an EB target wound (i.e., EB partial thickness wound of 10 cm2 to 50 cm2 in size aged =21 days and <9 months)
- •3. Patient and/or his/her legal representative has/have been informed, has/have read and understood the patient information/informed consent form, and has/have given written informed consent
- •4. Patient and/or his/her legal representative must be able and willing to follow study procedures and instructions
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 96
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 96
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •A patient will not be eligible to participate in this study if any of the following criteria apply:
- •1. Patient has EB subtype EBS
- •2. EB target wound that is > 9 months old or has clinical signs of local infection
- •3. Use of systemic antibiotics for wound-related infections within 7 days prior to enrolment
- •4. Administration of systemic or topical steroids (except for inhaled, ophthalmic or topical applications, such as budesonide suspension for oesophageal strictures [e.g., Pulmicort Respules® 0.25 mg/2 mL or 0.5 mg/2 mL]) within 30 days before enrolment
- •5. Immunosuppressive therapy or cytotoxic chemotherapy within 60 days prior to enrolment
- •6. Patient has undergone stem cell transplant or gene therapy for the treatment of inherited EB
- •7. Current and/or former malignancy including basal cell carcinomas and squamous cell carcinomas
- •8. Enrolment in any interventional study or treated with any investigational drug for any disease within 4 weeks prior to study entry
- •9. Factors present in the patient and/or his/her legal representative that could interfere with study compliance such as inability to attend scheduled study visits or compliance with home dressing changes
- •10. Pregnant or nursing women
- •11. Women of childbearing potential, including postmenarchal female adolescents, and men who are not willing to use an effective form of birth control with failure rates <1% per year (e.g., implant, injectable, combined oral contraceptive, intrauterine contraceptive device, sexual abstinence, vasectomy or vasectomised partner) during participation in the study (and at least 3 months thereafter)
- •12.Patient is a member of the investigational team or his/her immediate family
- •13.Patient lives in the same household as a study participant.
研究者
相似试验
进行中（未招募）
1 期
A Clinical Trial which compare the safety and efficacy of a wound gel, the study treatment, or a sunflower oil-based vehicle gel in patients with Inherited Epidermolysis Bullosa (EB)EUCTR2016-002066-32-HRAmryt Research Limited192
进行中（未招募）
1 期
A Clinical Trial which compare the safety and efficacy of a wound gel, the study treatment, or a sunflower oil-based vehicle gel in patients with Inherited Epidermolysis Bullosa (EB)Inherited Epidermolysis BullosaMedDRA version: 20.0Level: PTClassification code 10014989Term: Epidermolysis bullosaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2016-002066-32-ATAmryt Research Limited250
进行中（未招募）
1 期
A Clinical Trial which compare the safety and efficacy of a wound gel, the study treatment, or a sunflower oil-based vehicle (placebo) gel in patients with Inherited Epidermolysis Bullosa (EB)Inherited Epidermolysis BullosaMedDRA version: 20.0 Level: PT Classification code 10014989 Term: Epidermolysis bullosa System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2016-002066-32-GRAmryt Research Limited250
进行中（未招募）
1 期
A Clinical Trial which compare the safety and efficacy of a wound gel, the study treatment, or a sunflower oil-based vehicle gel in patients with Inherited Epidermolysis Bullosa (EB)Inherited Epidermolysis BullosaMedDRA version: 20.0Level: PTClassification code 10014989Term: Epidermolysis bullosaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2016-002066-32-IEAmryt Research Limited250
尚未招募
3 期
Efficacy and Safety Study with 24-month Follow-up of Oleogel-S10 in Patients a group of inherited disorders that involve the formation of blisters following trivial traumaEpidermolysis BullosaRBR-4vz9c4Hospital da Criança Santo Antônio - Irmandade Santa Casa de Misericórdia de Porto Alegre